Haemonetics Reports Q4 GAAP Loss on Impairment, Strong Adjusted EPS, Positive FY27 Guidance & $100M Share Buyback
Summary
Haemonetics reported a GAAP net loss for Q4 and FY26 due to an impairment charge, but delivered growth in adjusted earnings and issued positive fiscal 2027 guidance, complemented by a significant share repurchase.
Key Events
-
Q4 and FY26 Financial Results
The company reported a GAAP net loss of $(20.1) million or $(0.44) per diluted share for Q4 FY26, primarily due to a $77.2 million impairment of intangible assets. However, adjusted earnings per diluted share increased 4.0% to $1.29. For the full fiscal year 2026, GAAP EPS was $2.05, while adjusted EPS grew 8.5% to $4.96.
-
Positive Fiscal 2027 Guidance Issued
Haemonetics provided optimistic guidance for fiscal year 2027, projecting total reported revenue growth of 4-7% and organic revenue growth of 3-6%. The company also anticipates adjusted operating margin expansion of 50-100 basis points year-over-year and adjusted earnings per diluted share comparable to revenue growth.
-
Substantial Share Repurchase Program Activity
As part of its existing $500.0 million share repurchase program, the company repurchased 1,579,255 shares for $100.0 million during the fourth quarter of fiscal 2026. A remaining authorization of $325.0 million is available for future repurchases.
Analysis
Haemonetics reported a GAAP net loss for the fourth quarter and full fiscal year 2026, primarily driven by a significant non-cash impairment charge of $77.2 million related to the Attune Medical acquisition. Despite this, the company delivered growth in adjusted earnings per diluted share and provided positive fiscal year 2027 guidance, projecting revenue growth and adjusted operating margin expansion. Additionally, the company executed a substantial $100 million share repurchase in Q4, signaling management's confidence and commitment to returning capital to shareholders. Investors will likely focus on the underlying adjusted performance and the optimistic forward guidance, viewing the impairment as a one-time event.
At the time of this filing, HAE was trading at $54.35 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $2.4B. The 52-week trading range was $47.32 to $87.32. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.